ERBB2 and neoplasm: IHC4+C is a composite score incorporating immunohistochemical parameters ER, progesterone receptor (PgR), HER2 and Ki67 (IHC4) with a clinical treatment score (C) of tumour size, grade, nodal status and type of endocrine therapy developed on samples from the TransATAC cohort [3].